MONTREAL--(EON: Enhanced Online News)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma. This study is designed to evaluate the anti-tumor activity of ANG1005 as a new approach to treating primary brain cancers including recurrent glioblastoma multiforme (GBM) and anaplastic glioma. This Phase 2 clinical study follows a previously completed Phase 1 study of ANG1005 in patients with recurrent glioma in which promising signs of anti-tumor activity were observed.
“We are excited to advance ANG1005 into further clinical development for primary brain cancer”
“We are excited to advance ANG1005 into further clinical development for primary brain cancer,” said Jean-Paul Castaigne, MD, CEO of Angiochem. “There is a significant unmet need for innovative new treatments for recurrent gliomas such as GBM, one of the most common and most aggressive forms of primary brain cancer. In preclinical and early clinical studies, ANG1005 has demonstrated the ability to cross the blood brain barrier, offering the potential for significant benefit to this patient population with a very challenging cancer.”
This Phase 2 clinical study is designed to evaluate the anti-tumor activity of ANG1005 in up to 83 patients with recurrent high-grade glioma at approximately 10 U.S. clinical sites. Study endpoints include objective response rate, progression-free survival and median overall survival, in addition to safety and tolerability. For more information about the study please refer to www.clinicaltrials.gov.
ANG1005 is a novel paclitaxel-peptide drug conjugate that represents the first oncology product to leverage the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 200 patients in three clinical studies; two phase 1 studies where the product has shown tolerability similar to paclitaxel and indications of activity, and a Phase 2 study for which the intent-to-treat (ITT) analysis demonstrated encouraging signs of anti-tumor activity and was reported at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. A multi-study Phase 2 clinical program has been initiated to further confirm the clinical activity of ANG1005 observed in these earlier studies.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.